Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Genius Black-Ops... pure genius!!!
You know... I thought about how inappropriate it was for me to leave Remdesivir out of my daily update but, I did allude to the political science major... I’m sure he helped sway the FDA’s decision!!!
I purposely stayed away from the board today until now to see if the world would end before the market closed... sounds like Leronlimab is still less effective than water, investors are jumping ship out of fear of losing everything they invested, there’s been a raid on corporate office with arrests made, underlying technicals have made investing in CYDY like catching knives, and the company will never get the drug approved with current management... Did I miss anything else on today’s merry-go-round of misinformation, fear, uncertainty, and doubt? Have a great weekend everyone!!! Hopefully, they’ll allow CYDY to trade on Monday morning after the corporate office raid and the FDA won’t halt all of Leronlimab’s clinical trials because the political science major says they should...
Pretty sure he’s been given those responses... I want to know if he’ll ever comment on interfering with an FDA clinical trial!!! Fraudstein and FLAT NEWS needs to be held accountable for their actions!!!
Here’s my response to Adam... https://twitter.com/smileyriley_h/status/1299096487297798144?s=21
Everyone... Adam Fraudstein responded to one of Thomas Landstreet’s tweets challenging him about Leronlimab... I re-exposed his interference with an FDA clinical trial. If you’re on Twitter, please go to Fraudstein’s post and shove Leronlimab straight up his ass!!!!!!!!
I hate to be disrespectful to anyone but, I really don’t want to be a part of this particular storyline anymore.... but, I will answer your question Chuckles... There were no demands from OWS... In fact the woman who wrote the email asked if CytoDyn would be willing to meet with them for the purposes of discussing the science behind Leronlimab and management’s planned next steps along with how OWS might be able to support their efforts. That surmises the totality of the communication.
It’s only difficult to prove for people who wouldn’t believe it even if the e-mail were printed out and stapled to their forehead! No need to prove anything to those type of people anyway...
Thanks for showing the process so clearly... Let’s not mix words. Of course there’s a request by the company “applying” for consideration... an application, by definition, is a request!!! Theres also a very clear message from BARDA that they will either schedule a meeting or, they will not schedule a meeting and retain the technology for future reference... the fact is, there was enough merit in the science behind Leronlimab to warrant a request for a meeting from OWS with CytoDyn. Anything beyond that is pure speculation!
I have no knowledge of any decisions beyond the invitation by OWS to meet for discussions relating to Leronlimab and how they might support CytoDyn’s next steps...
I’ve already commented previously on the OWS letter so you know where I stand on that subject... as far as a retraction from the WSJ... that’s highly unlikely... With regards to the other issue regarding OWS, I am reluctant to speculate, but I believe this is a misunderstanding of semantics with Dr. Pourhassan... It was my understanding... and, I’m fairly certain a lot of discussion took place on this board regarding CytoDyn being listed on BARDA site a month or two ago... this listing would require filling out paperwork for Corona watch submission to BARDA. This step was required by any company to be considered for funding and logistical support... I don’t want to put words in Nader’s mouth but, I believe he intended to convey that CytoDyn had not applied for a grant with OWS or formally requested their support. As such, there has been nothing for BARDA to turn down... this goes back to my problem with the WSJ “Senior Administrative Official” statements... everything about those comments are inconsistent with where OWS would be in the process with CytoDyn if they were engaged in forward looking discussions IMO.
Yesterday I heard it was not appropriate to share unclassified information b/c, it artificially inflated the stock price... today I hear unsubstantiated claims that CYDY office is raided and arrests are being made along with a rejection from NASDAQ for uplisting... I suppose those claims aren’t irresponsible and don’t have an impact on the stock... I suppose anonymity brings with it great courage!
As a follow-on to my last comment... it probably was irresponsible for me to confirm the rumor that had been circulating regarding OWS when I stated that it wasn’t a rumor at all... At the time, the information I had was not reported to be confidential and I felt it was better to put an end to the rumor than to have individuals combating one another in an effort to prove the other wrong while making many nervous investors unsettled! Instead, my good intention backfired and a lot of energy went into trying to discredit my confirmation... I was even insulted personally on the board today and called a liar who couldn’t be trusted. But, in the end, what I stated was the truth... I know others on this board who also saw the letter... It wasn’t a fabrication or misrepresentation of the facts like some of the things reported by some “so-called” journalists... It’s lesson-learned on my part and I can assure you, it won’t happen again!
With that said, the WSJ did not conduct proper due-diligence and chose to interview a scientist for an extended period of time under the guise of showing interest in the diagnostics and the science behind Leronlimab then asking a nebulous question about the OWS and why he sold his shares of CYDY. His answers to both were truthful in that the OWS letter was sent to he and Dr. Pourhassan and that he had no idea what they were talking about with regards to selling shares and he hadn’t seen any paperwork regarding that... The WSJ reporter who has already misrepresented himself to CytoDyn contacted them for comment and they rightfully stiff-armed the reporter with “no comment”. The result of the interview was a distortion of the truth which we’ve unfortunately become accustomed to witnessing in this arena!!!
I’ve decided not to comment further on the board regarding this subject... I had already stated this previously which was met with suggestions that I was purposefully misrepresenting the truth... I believe I’ve said enough and everyone can make up their own mind what they want to believe about this topic and the science behind Leronlimab! Good luck to you all!!!
You may be right
Dr. Patterson just told me he spoke 30 minutes with that little peckerhead Wursthorn about diagnostics which is what he thought the article was supposed to be based on... (sound familiar? I’m sure this article simply “evolved” into something else) and was very upset with how the article turned out!!!
What I know from today... Dr. Pourhassan sure had me fooled if he is a stock pumper B’b/c, he was very convincing when he suggested people sell or, not buy CYDY if they didn’t believe in Leronlimab and its MOA... I won’t speak for everyone else, but I believe in Leronlimab’s MOA and can’t be fooled by failed attempts to misrepresent the truth from people like Adam Fraudstein or, irresponsible articles from The Wall Street Jerkoffs!!! GLTA with whatever decision you make in your CYDY investment!
Did you see Dr. Patterson’s manuscript sourced in the article?
Paraphrasing... if you don’t believe in Leronlimab MOA, you should sell... or, don’t buy if you’d don’t believe in Leronlimab! ataboy Dr. P!!!
Well... I guess sticky of an irresponsible WSJ article that wasn’t fact checked properly is better than unsubstantiated claims Dr. Pourhassan was a convicted felon!
No comment from CytoDyn when asked about OWS and not seeking grants aren’t exactly the same thing. I think we all (including the WSJ) are too far ahead of ourselves. If the timing of the meeting were to have occurred last week, it’s a bit premature to think the grant process should already be in the works...
There’s also a fairly significant conflict between the “senior officials comment” in the WSJ article and what was written in the e-mail to Dr. Pourhassan and Dr. Patterson... Mr. Zuckerman at the WSJ and I I have been exchanging communications this afternoon following the irresponsible article from Michael Wursthorn... I let Mr. Zuckerman know about that discrepancy and recommended they dig a little deeper than the “Senior Official” they referenced in their article to make sure they didn’t push this article out like the first one without having completed the proper due-diligence..
I do have the email. It was an exploratory communication following up from CYDY submission to BARDA. To summarize, the woman who wrote the email stated they were following up from the Corona watch submission to BARDA and the recent press release (from 8/11) to gain a better understanding of CYDY’s next steps and opportunities for collaboration... there was a leading virologist from BARDA and Sr. Science Advisor from NIH on the distribution. The content of the letter conflicts with the “senior officials” supposed statement about technical experts opting not to proceed further.
Beyond the letter, I have no idea if CYDY decided to engage with the group nor can I cconfirm if a meeting actually took place. Based on the date of the email, if a meeting took place, it would have likely happened last week.
This is the juxtaposition of it all NBL! There’s been so much misinformation and actual lies told in some instances by all the individuals reporting on CYDY that you can’t trust any of them! Wouldn’t it be a travesty if the article was the truth? The lack of journalistic integrity prevents anyone with a conscious from trusting them! Sad that the WSJ now can be compared to STAT and Citron!!!
I just wish I could trust the reporter! I will never trust him after the first article where I know he misrepresented facts! Every single company who has and/or will receive grant money from the OWS had to fill out the documents associated with BARDA. The letter written to Dr. Pourhassan and Dr. Patterson went beyond what the “senior officials” comments would indicate. There’s no way in hell that the meeting that would have taken place last week which included members from the following: USARMY/OS/ASPR/BARD/NIH/NIAID could be confirmed or denied by a “senior official” IMO
Believe it or not, I just got an e-mail from the other jackass (Zuckerman) involved in the original article at The Wall Street Journal making a dig at me!!! How’s that for journalistic integrity!!!
I distrust the journalist who wrote that article so, I would say he needs to show me a real reason why I should trust his word...
Journalists can’t walk back their words when they purposely misrepresent facts the public... Perfect examples of more notable journalists/news anchors are Dan Rather when he was fired from CBS News after misrepresenting facts associated with President Bush’s military service in 2004 and Brian Williams in 2015 after misrepresenting facts about his taking direct fire during the Iraq War in 2003... THAT’S WHY JOURNALISTIC INTEGRITY IS PARAMOUNT...
Both of these individuals have an outstanding body of work but, can you trust them now... Especially Dan Rather who really went after President Bush... If you research this story, you’ll learn how Rather let his ego and obsession with President Bush get in the way of the facts... Sound like another “so-called” journalist you’ve heard of from STAT News?
To reiterate... I wish we could trust all journalist... Unfortunately, it’s difficult to know what to trust from this article after the first one was riddled with inaccuracies and appeared engineered to match a narrative that was chosen before the article was ever written. As this interchange between myself and Michael Wursthorn prior to that article would indicate...
“There is some skepticism amongst many of the CytoDyn investors regarding your inquiry on Twitter. What can you tell me about the scope of your article and purpose of your interests?” Wursthorn’s final statement in his e-mail to me: “And to be clear, this isn't a CytoDyn story...it's looking broadly at biopharmaceutical stocks as they relate to covid.” Is that what the original article sounded like to any of you?
Journalistic integrity is paramount! Otherwise, there is an unbelievable skepticism preventing one from deciphering between what they can and cannot believe... Just like the “Little Boy That Cried Wolf”... This article makes me more disappointed knowing I can’t trust it than concerned it might be accurate...
CytoDyn couldn’t and wouldn’t comment at this point. It’s unfortunate that any crack opens the door for those willing to manipulate the facts. You just have to scratch your head in disbelief at times!
One would like to have enough confidence to trust the press! It’s unfortunate that this came out linked again to Micheal Wursthorn b/c, I don’t trust him as someone who wouldn’t stretch the truth... he was disingenuous when originally targeting CYDY for the first article while also leaving out numerous facts with a great deal of subjective information... Quoting “a senior official” is suspect based on the original article he co-authored... the conversation with the official could have happened or, it may not have... no way to know with absolute certainty! The bottom line is... How can you trust someone you already know to have misrepresented himself. That’s the problem with journalistic integrity and anyone who you know has used information to manipulate another person. You are either known as someone with integrity above reproach or, you walk through life as someone who can’t be trusted...
I confirmed Dr. Patterson’s manuscript completed its peer review and should be published in the near term... did not get what publication but, like the OWS letter, I trust the source
I look at CYDY as a “special situation”...at this point, market conditions have minimal impact to price fluctuations in the stock... IMO
CytoDyn must be doing something right... people like Adam Feuerstein weaponizing greed, gossip and jealousy in an effort to undermine a group of doctors and scientists working to do good in the world!!! Too bad for him, he didn’t know what he was doing when he took this assignment! Leronlimab is an absolutely pristine molecule that has Big Pharma in its sights!!! Fraudstein’s totally befuddled b/c, he doesn’t understand why nobody will listen to him anymore... boohoo... sad pathetic Adam, a hollow shell of himself from when he wrote his first hack piece on CytoDyn only a few short months ago... that man will never, ever be able to walk back trying to exploit a woman fighting for her life while he callously and directly interfered in an FDA clinical trial of Leronlimab! As the scientific and medical community continue to rally around Leronlimab, watch the fraudulent egomaniac self-implode as his dreams of being the “night king” of biotech turn into a humiliating “nightmare” instead!!! Doubt Leronlimab at your own peril... TickTock!!!
Yes, this is how the process started for each company that’s received funding and support or who will receive funding and support.
Hey SEE
This is all ya gonna get:
Date: Wed, Aug 12, 2020 at 8:30 AM
Subject: Operation Warp Speed /Corona Watch (UNCLASSIFIED)
You can either trust the word of a respected scientist who acknowledged the OWS e-mail was sent or, you can scurry the earth trying to find someone in the know that breaks the trust of the group
and shares it or, you can sell at the open tomorrow so you don’t have to worry about it anymore...
I’d appreciate anyone’s feedback that has valid feedback... We had SAE feedback in Phase 2 almost immediately... With the endpoints being 14 & 28 days mortality results... Based on the endpoints, wouldn’t the statistical analysis be more straightforward and readily available to CYDY and the FDA?